key: cord-0880100-4n1e2ric
authors: Zagorski, Karen; Pandey, Kabita; Rajaiah, Rajesh; Olwenyi, Omalla; Bade, Aditya; Acharya, Arpan; Johnston, Morgan; Filliaux, Shaun; Lyubchenko, Yuri; Byrareddy, Siddappa
title: Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of Concerns
date: 2022-01-24
journal: Res Sq
DOI: 10.21203/rs.3.rs-1206402/v1
sha: bede4908dc192b3446fb3599ec54cf79c49448bd
doc_id: 880100
cord_uid: 4n1e2ric

The current vaccine development strategies for the COVID-19 pandemic utilize whole inactive or attenuated viruses, virus-like particles, recombinant proteins, and antigen-coding DNA and mRNA with various delivery strategies. While highly effective, these vaccine development strategies are time-consuming and often do not provide reliable protection for immunocompromised individuals, young children, and pregnant women. Here, we propose a novel modular vaccine platform to address these shortcomings using chemically synthesized peptides and identified based on the validated bioinformatic data about the target. The vaccine is based on the rational design of an immunogen containing two defined B-cell epitopes from the spike protein of SARS-Co-V2 and a universal T-helper epitope PADRE assembled on the DNA scaffold. The results demonstrate that this assembly is immunogenic and generates neutralizing antibodies against SARS-CoV-2 wild type and its variants of concerns (VOC). This newly designed peptide nanoarray scaffold vaccine is useful in controlling virus transmission in immunocompromised individuals, as well as individuals who are prone to vaccine-induced adverse reactions. Given that the immunogen is modular, epitopes or immunomodulatory ligands can be easily introduced in order to tailor the vaccine to the recipient. This also allows the already developed vaccine to be modified rapidly according to the identified mutations of the virus.

The ongoing SARS-CoV-2 and its variants of concerns (VOCs) pandemic has demonstrated the need for vaccine technologies capable of ensuring rapid and e cient response to novel pathogens. Current vaccines for SARS-CoV-2 are extremely effective [1] [2] [3] [4] [5] , but their in ammatory nature limits the use in individuals with immune disorders 6-12 . Moreover, herd immunity towards novel pathogens has proven unreliable and di cult to achieve, leaving immunocompromised individuals at risk 13,14 . Immunocompromised individuals are at greater risk of infection and may remain infectious for longer than the immunocompetent, further increasing the rate of community spread [15] [16] [17] . This highlights the need for vaccine platforms that can be individualized and adapted for immunocompromised individuals and individuals with autoimmune disorders 18 . Vaccine development, production, and distribution are time-consuming and expensive, limiting their utility in ghting novel pathogens 19, 20 . The currently approved vaccines for SARS-CoV-2 are built upon prior developed SARS-CoV and MERS vaccines. Current vaccines utilize the critical knowledge about the immunopathological effects of targeting the nucleocapsid protein 21, 22 , as well as the 2p mutation used to stabilize the spike protein in the most immunogenic form 23 .

Conventional vaccines are composed of whole pathogens or their components. As a result, they can induce unwanted side effects, such as vaccine enhanced infection, interfering neutralization antibodies, Hoskins effect, toxicity, and pathogen de-attenuation [24] [25] [26] [27] [28] . These issues put the immunocompromised vaccine recipients at even greater risk and further hinder vaccine development 29 . Additionally, a certain percentage of current vaccine recipients experience cardiovascular complications such as in ammation and myocarditis 30, 31 . With these limitations in mind, we aim to develop a novel vaccinology approach such as a modular epitope vaccine as a proof-of-concept against SARS-CoV-2.

Our strategy is based on short peptide epitopes that generate immune responses precisely aimed at the critical components of the SARS-CoV-2, limiting the adverse effects [32] [33] [34] . The immunogen is assembled on a long single-stranded DNA molecule to which short DNA sequences (probes) are annealed in a sequence-speci c manner. Each DNA probe carries a speci c epitope (peptide) covalently attached to the end of the DNA. We used two peptides corresponding to well-identi ed linear epitopes of the S-protein on SARS-CoV-2 35 . To endow the vaccine with antigenicity Pan HLA DR-binding Epitope (PADRE), 36 was attached to the corresponding DNA probe incorporating it into the immunogen. As a result, the immunogen was obtained by annealing the long DNA template with a mixture of DNA-peptide conjugates. Several formulations of immunogen were made for immunization of mice to evaluate the Sprotein and the peptide-speci c immune responses. We found that our novel vaccine design generated an immune response in mice without any adverse events, and serum from these mice could neutralize SARS-CoV-2 and its VOCs. This study provides an insight into the applicability of this vaccine platform to SARS-CoV-2 and its VOCs.

Validation of neutralizing linear B-cell epitopes from the SARS-CoV-2 S-protein upon conjugation with DNA probes complementary to DNA scaffold.

The immunogen is assembled on a long DNA molecule, which acts as a scaffold to which short DNA oligonucleotides (probes) are annealed in a sequence-speci c manner (Fig. 1a) . Each DNA probe carries a speci c epitope (peptide) covalently conjugated to the end. The peptides are selected from reported neutralizing linear B-cell epitopes (peptides 2 and 3) from the SARS-CoV-2 S-protein 35 . These peptides are synthesized chemically, so any needed post-translational modi cation can be included in the peptide sequence. The DNA-peptide conjugate is annealed to a complementary sequence on the DNA scaffold.

Along with these DNA-peptide probes, a DNA conjugate containing the assembly of the T-helper epitope (PADRE, peptide 1) is annealed. The latter plays a critical role in T-helper-mediated immune response initiation and activation. The construct is obtained by annealing the long DNA scaffold with a 1:1 mixture of the DNA-peptide conjugates (peptides 1, 2, and 3) to yield the construct, as shown in Fig. 1a . The validation of the construct assembly as described above was obtained by spectrophotometric melting experiments. The melting pro le for this construct is a sharp increase in absorbance around 55°C corresponding to the experimental melting temperature (Fig. 1b) . The observed melting temperatures matched the expected melting temperatures predicted theoretically by OligoAnalyzer™ from Integrated DNA Technologies (52-57°C), which con rms the presence of a DNA duplex. The absence of hyperchromic effect at temperatures below 40°C suggests stability at physiological temperature (Fig. 1b) .

Immunogen conjugation to gold nanoparticles (GNP) with FR and PA methods generated particles with a higher density of the immunogen.

Conjugation to gold nanoparticles(GNP) was utilized to improve the uptake and biological stability of the construct 37 . We have used three strategies to conjugate GNP: a) freezing-based conjugation (FR), b) pHassisted conjugation (PA), and c) salt concentration-based conjugation (SC) as described in the methods section. The fourth formulation is the inulin-based formulation (IN), and it was used as a gold-free alternative since inulin microcrystals are known to improve antigen uptake 38 . The GNP-immunogen formulations are negatively-charged molecules with the net charge of particles de ned by the density of coverage of the nanoparticle by immunogens. Therefore, we used gel electrophoresis to characterize the formulations (Fig. 1c) . The immunogen GNP-PA exhibited the highest mobility towards the positive electrode, followed by the GNP-FR formulation, which had slightly lower mobility. The GNP-SC formulation produced a diffuse band with low electrophoretic mobility. Given that the GNP-immunogens mobility is proportional to the coverage of DNA, these results suggested that the immunogen conjugation with FR and PA methods produced particles with a high density of the immunogen compared to the SC method that produced particles with a low density of the immunogen. These validated immunogen formulations were further tested for their ability to induce an antigen-speci c immune response in mice.

GNP-conjugated immunogen by FR and PA methods elicited higher IgG immune response in mice sera against P1 and P2.

Four groups of BALB/C mice were immunized with the validated FR, PA, SC, and IN immunogen formulations (25 mg) with the CpG DNA adjuvant (100ul). Another group of mice received CpG DNA adjuvant alone as a control group. All ve groups of mice were immunized with three doses of the respective immunogen as prime dose (0 days), 1st boost (14 days,) and 2nd boost (28 days) as shown in schema (Fig. 2a ). Sera were collected at different immunization time points, including necropsy on day 61, and tested for the presence of IgG immune response against peptides 1 and 2 and whole S-protein using ELISA. Plates were coated separately with peptides 1 or 2 (0.1 mg/well) to determine the peptidespeci c IgG response. Sera from each time point were tested for IgG immune response starting with the dilution of 1:25 and serially diluted 5 folds up to 1:78125. Interestingly, sera from all the four groups, FR, PA, SC, and IN, indicated the presence of detectable IgG immune response against peptides 1 and 2 at 1:25 on day-61 (Fig. 2b & c) . However, mice immunized with immunogens formulated by FR and PA methods elicited higher IgG immune response against P1 and P2 with a maximal immune response on day 61. On the other hand, mice immunized with immunogen formulated with IN exhibited a higher IgG immune response against P1 than P2 (Fig. 2b & c) . Immunogen prepared with the SC method elicited a lower IgG immune response against both P1 and P2 (Fig. 2b & c) . The observed differential IgG immune response by immunogen produced with FR/PA and SC methods correlated with high and low-density immunogen particles (Fig. 1c) , respectively. These results indicate that immunogens with high-density particles elicit a higher immune response than immunogens with low-density particles. GNP-conjugated immunogen by FR and PA methods elicited higher IgG immune response in mice sera against S-protein.

Since the peptides in immunogen formulations are part of the SARS-CoV-2 S-protein, we asked the question of cross-reactivity of IgG immune response against S-protein. The position of the peptides P2 and P3 on SARS-CoV-2 S-protein is depicted in Supplementary Fig. S1 . We tested sera from all the groups of mice for IgG immune response against the entire S-protein and, as a control, tested against the Receptor-Binding Domain (RBD) protein. Like IgG immune response against P1 and P2, FR and PA immunogens elicited a higher immune response against the S-protein after the 2nd booster (Fig. 3a) . SC and IN immunogens also elicited detectable IgG immune response against the S-protein, although lower than the immunogens formulated by FR/PA methods. Further, to verify antigen-speci c IgG immune response, we tested the presence of IgG immune response against RBD of the S-protein. Since peptide epitopes were designed away from the RBD, sera from all the groups of mice failed to react with the RBD (Fig. 3b ).

GNP-conjugated immunogens in mice serum were able to neutralize live SARS-CoV-2 and its VOCs Since we found a good immune response against peptides and the full-length S protein, we asked whether this was responsible for the neutralization of SARS-CoV-2 and its variants. We pooled sera from all the mice and tested its neutralization capacity against two wild-type SARS-CoV-2 strains. SARS-CoV-2 isolates USA-WA1/2020 (Fig. 4a) , SARS-CoV-2 isolate USA-WI1/2020 (Fig. 4b) , and one VOC, SARS-CoV-2 isolate hCoV-19/USA/PHC658/2021 (Delta Variant) (Fig. 4c ). We found that at 1:25 to 100 dilutions, of sera could neutralize wild type and delta variants more than >50%. (Fig. 4) These data indicate that GNPconjugated vaccine candidates elicited antigen-speci c immune responses with neutralization potential.

No differential percentage in CD20+ B cells and CD4+/CD8+ T cells memory phenotypes observed across GNP-conjugated vaccine immunized groups.

Using a ow cytometric analysis, we performed a phenotypic assessment of CD4+ and CD8+ T cells and B cells in the spleen, and peripheral blood in control and GNP-conjugated vaccine immunized mice at necropsy. Here, CD4+ and CD8+ T cells phenotypic assessment was performed based on the surface expression of CD44 and CD62L (L-selectin) as memory phenotype and activation markers. The splenocytes and blood cells were stained with uorochrome-labeled anti-CD4, anti-CD8, anti-CD20, anti-CD44, and anti-CD62L antibodies, and representative gating was used to obtain CD4+ and CD8+ T cells to analyze the expression of CD44 and CD62L ( Supplementary Fig. S2 ). Although gated CD4+ and CD8+

T cells express comparable levels of CD44 and CD62L, no difference was observed in the percentage of naïve (CD44-CD62L+), TCM (CD44+CD62L+), and TE/EM (CD44+CDL-) in splenocytes and blood cells across immunized groups compared to control ( Supplementary Fig. S3 ). Further, splenocytes and blood cells from GNP-conjugated vaccine immunized mice did not exhibit the difference in the percentage of CD20+ B cells compared to control ( Supplementary Fig. S4 ).

This study demonstrated that peptides assembled on the DNA scaffold resulted in an e cient immunogen, producing a strong and speci c immune response (Fig. 1A) . The formulation of the immunogen is a crucial component for vaccine development. The modular vaccine was assembled by chemical conjugation to gold nanoparticles using three conjugation strategies or co-crystallization with inulin microcrystals. The electrophoresis data (Fig. 1C) suggests that the density of DNA coverage of the gold nanoparticle is the primary factor affecting the immunological e ciency of the GNP-immunogen construct. The thiol-gold coupling method de nes the nal product's density, which is consistent with the reported differences 39 . The acidic pH-based conjugation (PA) seemingly produced the highest coverage, closely followed by freezing-based (FR) conjugation. At the same time, the salt concentration-based method (SC) resulted in smearing and low mobility, suggesting low coverage and/or aggregation.

We tested the immunogenicity of the resulting vaccines and found stark differences between formulations. The inulin-based formulation had high anti-Peptide 1 antibody levels and a signi cantly weaker response to Peptide 2, suggesting dissociation of the immunogen molecule and ine cient immunological synapse formation. Peptide 1 serves as B-cell and T-helper epitope simultaneously and thus can form immunological synapses regardless of formulation and assembly. Salt concentrationbased SC formulation had a poor immune response to both peptides, suggesting poor uptake or processing by antigen-presenting cells due to aggregation or loss of antigen during dialysis. Finally, acid-(PA) and freezing-based (FR) formulations had almost identical antibody levels against both peptides P2 and P3, indicating the stability of the formulation. The developed peptide-array approach has several important features. The accessibility and affordability of solid-phase peptide synthesis of short peptide epitopes simplify the manufacturing of our vaccine 41 . We use programmed-complementarity DNA-based assembly of separate epitopes into a modular vaccine, which further improves adaptability, simpli es chemical synthesis and formulation. Most epitope vaccines utilize chemical conjugation of the epitopes to a carrier protein, such as ovalbumin, or combine the epitopes into a single fusion protein like beads on a string. Since the epitopes incorporated in such immunogens have no explicit borders, they can go through different patterns of proteolytic processing and produce a variety of new, uncharacterized, and unwanted epitopes, known as neoepitopes 42, 43 . The folding of these immunogens produces additional conformational neoepitopes, complicate storage and result in large batch-to-batch variability, should the arti cial protein have several stable structures 44 . The use of rigid DNA duplex for immunogen assembly keeps the epitopes in our vaccine structurally and spatially separated, minimizing the risk of neoepitope formation. Finally, DNA has low antigenicity and does not lead to carrier-induced epitope suppression 45, 46 . An epitope vaccine can generate a precise immune response to the neutralizing epitopes with high e cacy, with little or no therapeutically ine cient or harmful antibodies. This is critical when targeting some parts of the pathogen can lead to immune enhancement of the disease or adverse reactions. A well-targeted epitope vaccine allows for protection with minimal stimulation of the immune system [47] [48] [49] [50] . before an immunogen to be effective, it must contain the B cell target moieties on the surface and have the T-helper cell epitopes attached to them strongly enough to ensure simultaneous uptake into the immune cells. So far, several studies have reported the critical role of antigen-speci c B cells in the development and differentiation of CD4 T cells memory phenotypes [51] [52] [53] [54] . T-helper cells in mice can be categorized into memory and naïve phenotypes based on the expression level of CD44 and CD62L (L-selectin). CD44lowCD62L+ population considered as naive, CD44highCD62L+ population considered central memory (TCM), and the CD44highCD62Lpopulation considered effector and/or effector memory (TE/EM) 57, 58 . Although there were no differences in the percentage of T-helper memory phenotypes across the immunized group, the functionality of Thelper cells cannot be ruled out.

In conclusion, to our knowledge, this is the rst epitope vaccine made through DNA hybridization-based assembly of separate epitopes into a single molecule against SARS-CoV-2. The use of nucleic acids to achieve this is a very convenient strategy since they are non-toxic, easy to synthesize and characterize. Most importantly, they are highly programmable, allowing for reproducible and predictable assembly.

Since simple mixing of target epitopes and immunostimulants cannot e ciently deliver them to the antigen-presenting cells and facilitate the formation of an immunological synapse. Our newly developed platform greatly simpli es the fusion of immunomodulatory ligands, such as TLR agonists, allowing for direct delivery of these ligands into the immune cells. The use of fused TLR agonists is known to signi cantly improve vaccine e cacy 59,60 , allowing for T-cell-independent B-cell maturation 61 , which is important for elderly and immunocompromised patients, all while minimizing side effects effects 62,63 .

Vaccine preparation.

The peptides (N3-Lys)-GSAKFVAAWTLKAAA (peptide 1), corresponding to pan HLA DR-binding epitope PADRE, designed to stimulate T helper cells in genetically diverse populations), (N3-Lys)-FKEELDKYFKNH (peptide 2), corresponding to residues c of the full spike located right before heptad repeat 2 and is essential for the cell membrane fusion, (N3-Lys)-TESNKKFLPFQQ (peptide 3), corresponding to residues 553-564 of the full spike located on the S1, right after the RBD) have been synthesized by Genscript Vaccine formulation.

Vaccine candidates were formulated by freezing-based (FR), pH-assisted (PA), salt concentration-based (SC) conjugations, and inulin co-crystallization (IN). In the FR method, the annealing product was diluted in water 4-fold (<20mM Na + ) and added to the GNP stock solution (136 nM) at a molar ratio of 150:1. The mixture was placed in a -20°C freezer for 1 h. Then, the product was allowed to thaw, and 10 x PBS was added to adjust the tonicity of the nal product to isotonic. The solution was diluted to 50 nM (as GNP) in PBS, aliquoted at 100 µl/dose, and frozen for use as an immunogen.

In the PA method, the annealing product was combined with GNP stock solution at a molar ratio of 50:1 and incubated for 5 min. Then, pH was adjusted to 3.0 with 1M citric acid, incubated for 3 min, and neutralized with NaOH to pH 6.5. Heat annealing was performed as described previously. The conjugate was dialyzed against isotonic PBS, diluted, and aliquoted as in the FR method.

In the SC method, the initial procedure was identical to the FR method. Instead of freezing, saturated NaCl (6.15 M) was gradually added to a 1 M nal concentration (48 h). The conjugate was dialyzed against isotonic PBS, diluted, and aliquoted as in the FR method.

For IN co-crystallization conjugation, inulin microcrystals (epsilon form) were prepared as described in 64 . The microcrystals were washed ve times via centrifugation and resuspension in 45°C water. After the nal centrifugation, the wet pellet was resuspended in the annealed product at nal proportions of 300 mg of wet pellet and 5 moles of annealed product per 1 ml in isotonic PBS. The mixture was then heated up to 55°C and allowed to cool down slowly. The resulting microcrystals were aliquoted at 100 µl/dose and stored at 4°C until further use.

Agarose gel electrophoresis.

Agarose (2%) (Sigma-Aldrich, Inc. St. Louis, MO) gel was prepared in sodium borate buffer (10 mM, pH 8.0) and used for electrophoresis of unconjugated and conjugated GNP prepared by the FR, PA, and SC methods. The nanoparticles were loaded directly in buffer without loading dye at 10 µl/well, and electrophoresis was carried out at 15 V/cm (300 V).

Cells and viral titer determination. cells. The viral titer was determined using the plaque assay as described previously 65 . In brief, Vero E6 cells (2.510 ^5) were seeded in 6-well plates and incubated for 24 h. After 24 h, cells were washed with sterile 1X PBS, and the virus stock was ten-fold serially diluted in serum-free OptiMEM media and then added to the cells in duplicate. The plates were incubated at 37°C for 1 h with slight shaking every 15 minutes. Then, 2 ml of 0.5% agarose in minimal essential media (MEM) containing 5% FBS and antibiotics were added to each well and incubated at 37°C for 72 h. The cells were xed with 4% paraformaldehyde overnight, followed by removing the overlay and staining with 0.2% crystal violet to visualize plaque-forming units (PFU). All assays were performed in a BSL-3 laboratory setting. Analysis of B cells and CD4+/CD8+ memory phenotypes by ow cytometry.

Blood samples and spleen tissues were collected from immunized mice at necropsy. Single-cell suspension from spleen tissues was prepared, and RBCs were lysed using RBC lysis buffer. Cells (5x10 6 ) were washed and suspended in staining buffer, and Fc block was performed with puri ed anti-mouse CD16/32. Dead cells were discriminated by adding Zombie Aqua xable viability dye. Fluorochromelabeled mouse-speci c antibodies were diluted with staining buffer into cocktails and added to cells at 100 µl per sample. Cells were incubated for 30 min at room temperature and washed twice with staining buffer. Then, cells were xed using 2% PFA and acquired using the Becton Dickson Fortessa X450 ow cytometer. Fluorescence minus one (FMO) control was performed in parallel, and subsequent gating was determined by FMO. All data were analyzed using FlowJo software

Bars and error bars represent mean G standard error. Data were analyzed using GraphPad Prism (v6.07). IgG immune response against SARS-CoV-2 whole S-protein and RBD in mice immunized with GNPconjugated vaccine candidates. High binding 96 well plates were separately coated with whole S-protein and RBD (1 mg/ml) overnight at 4 °C. Sera prepared from different time immunization points were diluted and incubated for 1 h at room temperature. IgG immune response against the S-protein (A) and the RBD (B) was determined, as explained above. spike protein antibodies (rabbit mAb) and Alexa Fluor 488 goat anti-rabbit as primary and secondary antibodies, respectively. The nuclei were stained using Hoechst 33342 and plates were read using Operetta Imager. The percent neutralization was calculated based on the differential intensity of the uorescence.

SARS-CoV-2 VOCs map of mutations spanning from RBD to heptad repeat 2 (HR2)

The four spike protein variants: beta, gamma, delta, and omicron BA1, are represented schematically; note that the N-terminal domain and mutations localized within are omitted. Selected epitopes are expected to disrupt the activity of the subdomain 1 (SD1) and heptad repeat 2 (HR2), thus blocking viral attachment and cellular entry. The information about mutations is taken from the covdb.stanford.edu database.

This is a list of supplementary les associated with this preprint. Click to download.

SupplementaryFig2.tiff

Safety and E cacy of the BNT162b2 mRNA Covid-19

Safety and E cacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

E cacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Comparative Effectiveness of Moderna

Safety and e cacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

Acquired thrombotic thrombocytopenic purpura after rst vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine

Recurrence of Thrombotic Thrombocytopenic Purpura after mRNA-1273 COVID-19 Vaccine Administered Shortly after COVID-19. Konstantopoulos K, ed. Case Rep Hematol

Myocarditis and Pericarditis After Vaccination for COVID-19

Herd immunity to covid-19 may not be attainable in the UK A high vaccination rate will save many lives, but it probably won't be enough to stop covid-19 becoming a seasonal disease, nds Helen Thomson

Five reasons why COVID herd immunity is probably impossible

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants

SARS-CoV-2 late shedding may be infectious between immunocompromised hosts

Autoin ammatory and autoimmune conditions at the crossroad of COVID-19

Challenges of Developing Novel Vaccines With Particular Global Health Importance

Vaccine development for emerging infectious diseases

Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV

Vaccine E cacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants. Peiris J, ed

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Neutralization Interfering Antibodies: A "Novel" Example of Humoral Immune Dysfunction Facilitating Viral Escape? Viruses

Immunization with modi ed vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

Tuberculosis in Newborns: The Lessons of the

Vaccine-Derived Poliomyelitis 12 Years after Infection in Minnesota

Risk of Transmission Associated With Live Attenuated Vaccines Given to Healthy Persons Caring for or Residing With an Immunocompromised Patient

In ammation and Platelet Activation After COVID-19 Vaccines -Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A Meta-Analysis and Systematic Review

Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines

Editorial: Epitope Discovery and Synthetic Vaccine Design

Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate

Gold nanoparticle-based platforms for vaccine development

Delta inulin: a novel, immunologically active, stable packing structure comprising -D-[2 -> 1] poly(fructo-furanosyl) -D-glucose polymers

Freezing Directed Construction of Bio/Nano Interfaces: Reagentless Conjugation, Denser Spherical Nucleic Acids, and Better Nano ares

Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses

Peptide-based synthetic vaccines

What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development

An optimized antigen-protein fusion

A comparison of the immunogenicity of the native and denatured forms of a protein

A DNA Nanostructure Platform for Directed Assembly of Synthetic Vaccines

Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-speci c antibodies

Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety

The promise and challenge of epitope-focused vaccines. Hum Vaccines Immunother

More than one reason to rethink the use of peptides in vaccine design

Peptide Vaccines: New Trends for Avoiding the Autoimmune Response

A critical role for B cells in the development of memory CD4 cells

Requirement of B cells for generating CD4+ T cell memory

Antigen-speci c B cells are required for the secondary response of T cells but not for their priming

Anergy in memory CD4+ T cells is induced by B cells

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

Delineation of antigen-speci c and antigen-nonspeci c CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy

Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

Central memory and effector memory T cell subsets: function, generation, and maintenance

Flagellin Fusion Proteins as Adjuvants or Vaccines Induce Speci c Immune Responses

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

TLR4-and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice

Development of VAX128, a recombinant hemagglutinin (HA) in uenza-agellin fusion vaccine with improved safety and immune response

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modi cations, and Adjuvant-Antigen Codelivery

The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions

Two Detailed Plaque Assay Protocols for the Quanti cation of Infectious SARS-CoV-2

Three epitopes as peptides (P) 1, 2, and 3 are assembled on a DNA scaffold containing thiol for coupling with gold. According to Fig. S1, P1 is a universal T helper cell epitope PADRE, P2 is the S-protein-derived peptide (residues 1148-1159), important for cell membrane fusion, and P3 is the peptide located after RBD (residues 553-564), important for receptor recognition (A)

260 nm and the melting curve was taken at a temperature range from 10 to 85°C (B). Immunogen-gold formulations generated by different methods characterized by agarose gel electrophoresis. From top to bottom: free gold nanoparticles, freezing-based conjugation of immunogen, acid-based conjugation

IgG immune response against P1 and P2 in mice immunized with GNP-conjugated vaccine candidates

High protein binding 96 well plates were separately coated with P1 and P2 (100 ng/well) overnight at 4 °C. Sera prepared from different time points of immunization were diluted and incubated for 1 h at room temperature. IgG immune response against P1 (B) and P2 (C) was determined using HRP-conjugated goat anti-mouse

The work was supported by grants to YLL from NSF (MCB 1515346) and NIH (5U54GM115458-05) to YLL and SNB. The authors thank T. Stormberg and other members of Lyubchenko lab for useful insights in the data interpretation. This work was partially supported by National Institute of Allergy and Infectious Diseases grants R01 AI113883, and DA052845.